Laboratory Testing for Liver Disease

Zakim and Boyer's Hepatology

Volumn , Issue , 2006, Pages 235-250

  Poynard, Thierry ^a   Imbert Bismut, Françoise ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 42649135302     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3258-8.50019-X     Document Type: Chapter

References (171)

1. Pratt DS, Kaplan MM Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000, 342:1266.
2. Aranda-Michel J, Sherman KE Tests of the liver: use and misuse. Gastroenterologist 1998, 6:34.
3. Afdhal NH Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis?. Clin Chem 2004, 50:1299-1300.
4. Bacq Y, Zarka O, Brechot JF, et al. Liver function tests in normal pregnancy: a prospective study of 103 pregnant women and 103 matched controls. Hepatology 1996, 23:1030.
5. Rej R. Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues. Clin Chem 1978, 24:1971.
6. Kew MC Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 2000, 355:591.
7. Foust RT, O'Brien JF, Schiff ER Isolated aspartate aminotransferase elevation due to macroenzyme formation with liver biopsy correlation. Am J Gastroenterol 1990, 85:88.
8. Ohtsuki T, Inui T, Andoh A, et al. Characteristics of aspartate aminotransferase binding immunoglobulin determined by the isotope method. J Lab Clin Med 1994, 124:218-223.
9. Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 1998, 27:1213.
10. Halfon P, Imbert-Bismut F, Messous D, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002, 2:3-7.
11. Johnson RD, O'Connor ML, Kerr RM Extreme serum elevations of aspartate aminotransferase. Am J Gastroenterol 1995, 90:1244.
12. Whitehead MW, Hawkes ND, Hainsworth I, et al. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut 1999, 45:129.
13. Flora KD, Keeffe EB Evaluation of mildly abnormal liver tests in asymptomatic patients. J Insur Med 1990, 22:206.
14. Hultcrantz R, Glaumann H, Lindberg G, et al. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986, 21:109.
15. Van Ness NM, Diehl AM Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?. Ann Intern Med 1989, 111:473.
16. Friedman LS, Dienstag JL, Watkins E, et al. Evaluation of blood donors with elevated serum alanine aminotransferase levels. Ann Intern Med 1987, 107:137.
17. Katkov WN, Friedman LS, Cody H, et al. Elevated serum alanine aminotransferase levels in blood donors: the contribution of hepatitis C virus. Ann Intern Med 1991, 115:882.
18. Daniel S, Ben-Menachem T, Vasudevan G, et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999, 94:3010.
19. Briere RO Serum ALT levels: effect of sex, race, and obesity on unit rejection rate. Transfusion 1988, 28:392.
20. Hetland G, Holme I, Stromme JH Co-variation of alanine aminotransferase levels with relative weight in blood donors. Scand J Clin Lab Invest 1992, 52:51.
21. Hay JE, Czaja AJ, Rakela J, et al. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989, 9:193.
22. Palmer M, Shaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990, 99:1408.
23. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004, 53:413-419.
24. Helfgott SM, Karlson E, Beckman E Misinterpretation of serum transaminase elevation in 'occult' myositis. Am J Med 1993, 95:447.
25. Fallon KE, Sivyer G, Sivyer K, et al. The biochemistry of runners in a 1600 km ultramarathon. Br J Sports Med 1999, 33:264-269.
26. Patwardhan RV, Smith OJ, Farmelant MH Serum transaminase levels and cholescintigraphic abnormalities in acute biliary tract obstruction. Arch Intern Med 1987, 147:1249.
27. Ruttimann S, Dreifuss M, Clemencon D, et al. Multiple biochemical blood testing as a case-finding tool in ambulatory medical patients. Am J Med 1993, 94:141.
28. Goddard CJ, Warnes TW Raised liver enzymes in asymptomatic patients: investigation and outcome. Dig Dis 1992, 10:218.
29. Bhavnani M, Lloyd D, Bhattacharyya A, et al. Screening for genetic haemochromatosis in blood samples with raised alanine aminotransferase. Gut 2000, 46:707.
30. Bardella MT, Vecchi M, Conte D, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology 1999, 29:654.
31. Rivera-Nieves J, Kozaiwa K, Parrish CR, et al. Marked transaminase elevation in anorexia nervosa. Dig Dis Sci 2000, 45:1959.
32. Bonamico M, Pitzalis G, Culasso F. Hepatic damage during coeliac disease in childhood. Minerva Pediatr 1986, 38:959.
33. Mugica F, Castiella A, Otazua P, et al. Prevalence of coeliac disease in unexplained chronic hypertransaminasemia. Rev Esp Enferm Dig 2001, 93:707-714.
34. Volta U, Granito A, De Franceschi L, et al. Anti tissue transglutaminase antibodies as predictors of silent coeliac disease in patients with hypertransaminasaemia of unknown origin. Dig Liver Dis 2001, 33:420-425.
35. Kundrotas LW, Clement DJ Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. Dig Dis Sci 1993, 38:2145.
36. Cohen JA, Kaplan MM The SGOT/SGPT ratio - an indicator of alcoholic liver disease. Dig Dis Sci 1979, 24:835.
37. Matloff DS, Selinger MJ, Kaplan MM Hepatic transaminase activity in alcoholic liver disease. Gastroenterology 1980, 78:1389.
38. Reedy DW, Loo AT, Levine RA ASTALT ratio >1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998, 43:2156.
39. Imperiale TF, Said AT, Cummings OW, et al. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000, 95:2328.
40. Giannini E, Botta F, Fasoli A, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999, 44:1249.
41. Sheth SG, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998, 93:44.
42. Sorbi D, Boynton J, Lindor KD The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999, 94:1018.
43. Ludwig S, Kaplowitz N. Effect of pyridoxine deficiency on serum and liver transaminases in experimental liver injury in the rat. Gastroenterology 1980, 79:545.
44. Nalpas B, Vassault A, Charpin S, et al. Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: diagnostic value and interpretation in a liver unit. Hepatology 1986, 6:608.
45. Yasuda K, Okuda K, Endo N, et al. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Gastroenterology 1995, 109:1295.
46. Millan JL On codevelopmental expression and structure of alkaline phosphatase genes. Anticancer Res 1988, 8:995.
47. Simko V. Alkaline phosphatases in biology and medicine. Dig Dis 1991, 9:189.
48. Hagerstrand I. Distribution of alkaline phosphatase activity in healthy and diseased human liver tissue. Acta Pathol Microbiol Scand A 1975, 83:519.
49. Gordon T. Factors associated with serum alkaline phosphatase level. Arch Pathol Lab Med 1993, 117:187.
50. Reichling JJ, Kaplan MM Clinical use of serum enzymes in liver disease. Dig Dis Sci 1988, 33:1601.
51. Lieberman D, Phillips D. 'Isolated' elevation of alkaline phosphatase: significance in hospitalized patients. J Clin Gastroenterol 1990, 12:415.
52. Clubb JS, Neale FC, Posen S The behavior of infused placental alkaline phosphatase in human subjects. J Lab Clin Med 1965, 66:493.
53. Kaplan MM, Righetti A Induction of rat liver alkaline phosphatase: the mechanism of the serum elevation in bile duct obstruction. J Clin Invest 1970, 49:508.
54. Seetharam S, Sussman NL, Komoda T, et al. The mechanism of elevated alkaline phosphatase activity after bile duct ligation in the rat. Hepatology 1986, 6:374.
55. George GO, Spiegelman GA, Barkin JS Normal serum alkaline phosphatase: an unusual finding in early suppurative biliary obstruction. Am J Gastroenterol 1993, 88:771.
56. Cooper JF, Brand EJ Symptomatic sclerosing cholangitis in patients with normal alkaline phosphatase: two case reports and a review of the literature. Am J Gastroenterol 1988, 83:308.
57. Maldonado O, Demasi R, Maldonado Y, et al. Extremely high levels of alkaline phosphatase in hospitalized patients. J Clin Gastroenterol 1998, 27:342.
58. Wilson JW Inherited elevation of alkaline phosphatase activity in the absence of disease. N Engl J Med 1979, 301:983.
59. Goldberg DM, Martin JV Role of γ-glutamyl transpeptidase activity in the diagnosis of hepatobiliary disease. Digestion 1975, 12:232.
60. Meister A. Glutathione and the γ-glutamyl cycle. Glutathione: metabolism and function 1976, 35. Raven Press, New York. I.M. Arias, W.B. Jakoby (Eds.).
61. Tate SS, Thompson GA, Meister A Recent studies on γ-glutamyl transpeptidase. Glutathione: metabolism and function 1976, 45. Raven Press, New York. I.M. Arias, W.B. Jakoby (Eds.).
62. Wenham PR, Price CP, Sammons HG γ-Glutamyl-transferase isoenzymes in human bile. J Clin Pathol 1978, 31:666.
63. Penn R, Worthington DJ Is serum γ-glutamyl-transferase a misleading test?. BMJ 1983, 286:531.
64. Whitfield JB, Pounder RE, Neale G, et al. Serum γ-glutamyl transpeptidase activity in liver disease. Gut 1972, 13:702.
65. Kajiwara E, Akagi K, Tsuji H, et al. Low gamma-glutamyltranspeptidase activity in patients with acute intrahepatic cholestasis. Gastroenterol Jpn 1981, 16:76-81.
66. Yoshida H, Sakuma H, Morito T, et al. No elevation of serum gamma-glutamyl transpeptidase level in a polymyositis case with intrahepatic cholestasis. Nippon Shokakibyo Gakkai Zasshi. 1983, 80:2224-2227.
67. Jansen PLM, Müller M. The molecular genetics of familial intrahepatic cholestasis. Gut 2000, 47:1.
68. Lachaux A, Loras-Duclaux I, Bouvier R, et al. Benign recurrent cholestasis with normal gamma-glutamyl-transpeptidase activity. J Pediatr 1992, 121:78.
69. Van Ooteghem NA, Klomp LW, van Berge-Henegouwen GP, et al. Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: low GGT cholestasis is a clinical continuum. J Hepatol 2002, 36:439-443.
70. Keeffe EB, Sunderland MC, Gabourel JD Serum gamma-glutamyl transpeptidase activity in patients receiving chronic phenytoin therapy. Dig Dis Sci 1986, 31:1056.
71. Zien M, Discombe G. Serum γ-glutamyl transpeptidase as a diagnostic aid. Lancet 1970, 2:748.
72. Moussavian SN, Becker RC, Pipmeyer JL, et al. Serum gamma-glutamyl transpeptidase and chronic alcoholism: influence of alcohol ingestion and liver disease. Dig Dis Sci 1985, 30:211.
73. Jeng K-S, Sheen I-S, Tsai Y-C Gamma-glutamyl transpeptidase messenger RNA may serve as a diagnostic aid in hepatocellular carcinoma. Br Med J 2001, 88:986.
74. Tiribelli C, Ostrow JD New concepts in bilirubin chemistry, transport and metabolism: report of the Second International Bilirubin Workshop, 9-11 April 1992, Trieste, Italy. Hepatology 1993, 17:715.
75. van den Bergh HAA, Muller P Uber ein direkte und indirekte Diazoreaktion auf Bilirubin. Biochem Zeitschr 1916, 77:93.
76. Malloy HT, Evelyn KA The determination of bilirubin with the photoelectric colorimeter. J Biol Chem 1937, 119:481.
77. Weiss JS, Gautam A, Lauff JJ, et al. The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. N Engl J Med 1983, 309:147.
78. Child CG, Turcotte JG Surgery and portal hypertension. The liver and portal hypertension 1964, 50. WB Saunders, Philadelphia. C.G. Child (Ed.).
79. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989, 10:1.
80. O'Grady JG, Alexander GJM, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989, 97:439.
81. Hofmann AF The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999, 159:2647.
82. Trauner M, Meier PJ, Boyer JL Molecular pathogenesis of cholestasis. N Engl J Med 1998, 339:1217.
83. Berk PD, Javitt NB Hyperbilirubinemia and cholestasis. Am J Med 1978, 64:311.
84. Poupon RE, Chretien Y, Poupon R, et al. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993, 17:599.
85. Skrede S, Blomhoff JP, Elgjo K, et al. Biochemical tests in evaluation of liver function. Scand J Gastroenterol 1973, 19(Suppl):37.
86. Kirsch R, Frith L, Black E, et al. Regulation of albumin synthesis and catabolism by alteration of dietary protein. Nature 1968, 217:578.
87. Keshgegian AA Hypoalbuminemia associated with diffuse hypergammaglobulinemia in chronic diseases: lack of diagnostic specificity. Am J Clin Pathol 1984, 81:477.
88. Ballmer PE, Walshe D, McNurlan MA, et al. Albumin synthesis rates in cirrhosis: correlation with Child-Turcotte classification. Hepatology 1993, 18:292.
89. Rothschild MA, Oratz M, Zimmon D, et al. Albumin synthesis in cirrhotic subjects with ascites studied with carbonate 14C. J Clin Invest 1969, 48:344.
90. Oratz M, Rothschild MA, Schreiber SS Alcohol, amino acids, and albumin synthesis. III. Effects of ethanol, acetaldehyde, and 4-methylpyrazole. Gastroenterology 1978, 74:672-676.
91. Suttie JW, Jackson CM Prothrombin structure, activation and biosynthesis. Physiol Rev 1977, 57:1.
92. Quick AJ Hemorrhagic diseases and thrombosis 1966, 391. Lea & Febiger, Philadelphia. 3rd edn.
93. Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978, 75:193.
94. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646.
95. Ratnoff OD Hemostatic mechanisms in liver disease. Med Clin North Am 1963, 47:721.
96. Stenflo J, Ferlund P, Egan W, et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 1974, 71:2730.
97. Lord JW, Andrus WdeW Differentiation of intrahepatic and extrahepatic jaundice. Response of the plasma prothrombin to intramuscular injection of menadione (2-methyl-1,4-naphthoquinone) as a diagnostic aid. Arch Intern Med 1941, 68:199.
98. Schmidt LE, Knudsen TT, Dalhoff K, et al. Effect of acetylcysteine on prothrombin index in paracetamol poisoning without hepatocellular injury. Lancet 2002, 360:1151-1152.
99. Blanchard RA, Furie BC, Jorgensen M, et al. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981, 305:242.
100. Weitz IC, Liebman HA Desγ-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993, 18:990.
101. Ishii M, Gama H, Chida N, et al. Simultaneous measurements of serum α-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. Am J Gastroenterol 2000, 95:1036.
102. Nomura F, Ishijima M, Kuwa K, et al. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999, 94:650.
103. Okuda H, Nakanishi T, Takatsu K, et al. Measurement of serum levels of desγ-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 1999, 85:812.
104. Goldberg DM 5'-Nucleotidase: recent advances in cell biology, methodology and clinical significance. Digestion 1973, 8:87.
105. Cassidy WM, Reynolds TB Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol 1994, 19:118.
106. Van Waes L, Lieber CS Glutamate dehydrogenase: a reliable marker of liver cell necrosis in the alcoholic. Br Med J 1977, 2:1508.
107. Jenkins WJ, Rosalki SB, Foo Y, et al. Serum glutamate dehydrogenase is not a reliable marker of liver cell necrosis in alcoholics. J Clin Pathol 1982, 35:207.
108. Afdhal NH Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests?. Hepatology 2003, 37:972-974.
109. Dienstag J. The role of liver biopsy in chronic hepatitis C. Hepatology 2002, 36:S152-S160.
110. Bravo AA, Sheth SG, Chopra S Liver biopsy. N Engl J Med 2001, 344:495-500.
111. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
112. Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003, 39:239-244.
113. Bedossa P, Dargère D, Paradis V Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
114. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000, 14:543-548.
115. Poynard T, McHutchison J, Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003, 38:481-492.
116. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004, 50:1344-1355.
117. Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: A systematic review. Hepatology 2002, 36:S161-S172.
118. Imbert-Bismut F, Ratziu V, Laurence Pieroni L, et al. for the MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075.
119. Poynard T, Imbert-Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by Hepatitis C Virus: Longitudinal validation in a randomized trial. J Viral Hepatitis 2002, 9:128-133.
120. Myers RP, Ratziu V, Imbert-Bismut F, et al. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002, 97:2419-2425.
121. Myers RP, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients. AIDS 2003, 17:1-5.
122. Myers RP, de Torres M, Imbert-Bismut F, et al. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count and the age-platelet index. Dig Dis Sci 2003, 48:146-153.
123. Thabut D, Simon M, Myers RP, et al. Non invasive prediction of fibrosis in patients with chronic hepatitis C. [Letter] Hepatology 2003, 37:1220-1221.
124. Le Calvez S, Thabut D, Messous D, et al. Fibrotest has higher predictive values than APRI for fibrosis diagnosis in patients with chronic hepatitis C. [Letter] Hepatology 2004, 39:862-863.
125. Halfon P, Imbert-Bismut F, Messous D, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002, 1:3-7.
126. Rossi E, Adams L, Prins A, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003, 49:450-454.
127. Imbert-Bismut F, Messous D, Thibaut V, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004, 42:323-333.
128. Munteanu M, Messous D, Thabut D, et al. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (Fibrotest) and activity (Actitest). Comp Hepatol 2004, 3:3.
129. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994, 20:15-20. National Institutes of Health Consensus Development Conference Statement.
130. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
131. Poynard T, Imbert-Bismut F, Ratziu V, et al. Fibrotest even better than liver biopsy? Clin Chem 2003. Electronic letter Response: (21 March 2003) . http://www.clinchem.org/cgi/eletters/49/3/450.
132. Poynard T. Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C. [Letter] Gut 2003, 52:1532.
133. Callewaert N, Van Vlierberghe H, Van Hecke A, et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nature Med 2004, 10:1-6.
134. Poynard T, Imbert-Bismut F, Ratziu V. Serum markers of liver fibrosis. Hepatol Rev 2004, 1:25-33.
135. Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003, 39:222-230.
136. McIntyre N. Plasma lipids and lipoproteins in liver disease. Gut 1978, 19:526.
137. Day RC, Harry DS, Owen JS, et al. Plasma lecithin: cholesterol-acyltransferase activity and the lipoprotein abnormalities of liver disease. Scand J Clin Lab Invest 1978, 150:223.
138. Freeman M, Kuiken L, Ragland JB, et al. Hepatic triglyceride lipase deficiency in liver disease. Lipids 1977, 12:443.
139. Fukushima N, Yamamoto K, Ozaki I, et al. Apolipoprotein A-I, E, C-III and LDL-receptor mRNA expression in liver diseases. Nippon Rinsho 1993, 51:407-413.
140. Obici L, Palladini G, Giorgetti S, et al. Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology 2004, 126:1416-4122.
141. Switzer S. Plasma lipoproteins in liver disease: I. Immunologically distinct low-density lipoproteins in patients with biliary obstruction. J Clin Invest 1967, 46:1855.
142. Seidel D, Alauprovic P, Furman RH A lipoprotein characterizing obstructive jaundice: I. Method for quantitative separation and identification of lipoproteins in jaundiced subjects. J Clin Invest 1969, 48:1211.
143. Sörös P, Böttcher J, Maschek H, et al. Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia. Hepatology 1998, 28:1199.
144. Jahn CE, Schaefer EJ, Taam LA, et al. Lipoprotein abnormalities in primary biliary cirrhosis: association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985, 89:1266.
145. Pawlotsky JM, Bouvier-Alias M, Hezode C, et al. Standardization of hepatitis C virus RNA quantification. Hepatology 2000, 32:654-659.
146. Pawlotsky JM Molecular diagnosis of viral hepatitis. Gastroenterologys 2002, 122:1554-1568.
147. Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely 'occult'?. Hepatology 2001, 34:194-203.
148. Bassett ML, Halliday JW, Ferris RA, et al. Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests. Gastroenterology 1984, 87:628-633.
149. Bacon BR Hemochromatosis: diagnosis and management. Gastroenterology 2001, 120:718-725.
150. Tavill AS Diagnosis and management of hemochromatosis. Hepatology 2001, 33:1313-1321.
151. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 1:929-938.
152. Czaja AJ, Freese DK Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002, 36:479-497.
153. Van de Water J, Cooper A, Surh SC, et al. Detection of autoantibodies ro recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med 1989, 320:1377-1380.
154. Wiesner RH, LaRusso NF, Ludwig J, et al. Comparison of the clinicopathological features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 1985, 88:108-114.
155. MacLachlan MJ, Rodnan GP, Cooper WM, et al. Chronic active ('lupoid') hepatitis: a clinical, serological, and pathological study of 20 patients. Ann Intern Med 1965, 62:425.
156. McFarlane IG, Smith HM, Johnson PJ, et al. Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?. Lancet 1990, 335:754.
157. Mitchel LS, Jeffers LJ, Reddy KR, et al. Detection of hepatitis C virus antibody by first and second generation assays and polymerase chain reaction in patients with autoimmune chronic active hepatitis types I, II, and III. Am J Gastroenterol 1993, 88:1027.
158. Demeulenaere L, Wieme RJ Special electrophoretic anomalies in the serum of liver patients: a report of 1145 cases. Am J Dig Dis 1961, 6:661.
159. Rowntree LG, Hurwitz SH, Bloomfield AL An experimental and clinical study of the value of phenoltetrachlorphthalein as a test of hepatic function. Bull Johns Hopkins Hosp 1913, 24:327.
160. Rosenthal SM, White EC Clinical application of bromsulphthalein test for hepatic function. JAMA 1925, 84:1112.
161. Cherrick GR, Stein SW, Leevy CM, et al. Indocyanine green: observations on its physical properties, plasma decay and hepatic extraction. J Clin Invest 1960, 39:592.
162. Leevy CM, Smith F, Longueville J, et al. Indocyanine green clearance as a test for hepatic function: evaluation by dichromatic ear densitometry. JAMA 1967, 200:236.
163. Ishigami Y, Masuzawa M, Miyoshi E, et al. Clinical applications of ICG finger monitor in patients with liver disease. J Hepatol 1993, 19:232.
164. Therapondos G, Plevris JN, Stanley AJ, et al. Cerebral near infrared spectroscopy for the measurement of indocyanine green elimination in cirrhosis. Aliment Pharmacol Ther 2000, 14:923.
165. Jiao LR, El-Desoky AA, Seifalian AM, et al. Effect of liver blood flow and function on hepatic indocyanine green clearance measured directly in a cirrhotic animal model. Br J Surg 2000, 87:568.
166. Poulsen HE, Loft S Antipyrine as a model drug to study hepatic drug-metabolizing capacity. J Hepatol 1988, 6:374.
167. Opekun AR, Klein PD, Graham DY [13C]Aminopyrine breath test detects altered liver metabolism caused by low-dose oral contraceptives. Dig Dis Sci 1995, 40:2417.
168. Jover R, Carnicer F, Sánchez-Pajá J, et al. Salivary caffeine clearance predicts survival in patients with liver cirrhosis. Am J Gastroenterol 1997, 92:1905.
169. Ballmer PE, Reichen J, McNurlan MA, et al. Albumin but not fibrinogen synthesis correlates with galactose elimination capacity in patients with cirrhosis of the liver. Hepatology 1996, 24:53.
170. Rypins EB, Henderson JM, Fulenwider JT, et al. A tracer method for measuring rate of urea synthesis in normal and cirrhotic subjects. Gastroenterology 1980, 78:1419.
171. Ercolani G, Grazi GL, Callivà R, et al. The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery. Surgery 2000, 127:464.